Literature DB >> 8191238

Seroreactivity to Pneumocystis carinii in patients with AIDS versus other immunosuppressed patients.

K Elvin1, A Björkman, N Heurlin, B M Eriksson, L Barkholt, E Linder.   

Abstract

The aim was to study the humoral response to Pneumocystis carinii and its diagnostic use in patients with P. carinii pneumonia (PCP). The antibody response was measured by indirect immunofluorescence in AIDS patients versus other immunosuppressed patients with 122 episodes of confirmed PCP. During the early acute stage of the pneumonia, anti-P. carinii antibodies were found in 17% of AIDS and 24% of other immunosuppressed patients. In the second serum sample, antibodies were still found in 17% of the AIDS patients but in as many as 56% of the otherwise immunosuppressed patients. Antibodies were also found in 17% of HIV-positive and 15% of other immunosuppressed control patients, but only in 3% of immunocompetent controls (p < 0.001). Paired sera were available from 55 patients during 58 PCP episodes. Seroconversion or a fourfold rise in titre was detected in only 1/36 (3%) AIDS patients but in 10/22 (45%), (95% c.i.: 24-66%) other immunosuppressed patients (p < 0.001). We conclude that AIDS patients seem to have lost their ability to develop a humoral response to P. carinii during pneumonia, whereas many other immunosuppressed patients do respond. In these patients the serological test against P. carinii was of no diagnostic value in the acute phase of the infection, whereas when analysing paired sera it was a useful complement to the clinical diagnosis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8191238     DOI: 10.3109/00365549409008588

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  10 in total

Review 1.  Immunological features of Pneumocystis carinii infection in humans.

Authors:  P D Walzer
Journal:  Clin Diagn Lab Immunol       Date:  1999-03

2.  Transmission of Pneumocystis carinii from patients to hospital staff.

Authors:  B Lundgren; K Elvin; L P Rothman; I Ljungström; C Lidman; J D Lundgren
Journal:  Thorax       Date:  1997-05       Impact factor: 9.139

3.  Human immunodeficiency virus-infected patients with prior Pneumocystis pneumonia exhibit increased serologic reactivity to several major surface glycoprotein clones.

Authors:  K R Daly; J V Koch; N J Shire; L Levin; P D Walzer
Journal:  Clin Vaccine Immunol       Date:  2006-10

Review 4.  Diagnosing Pneumocystis jirovecii pneumonia: A review of current methods and novel approaches.

Authors:  Marjorie Bateman; Rita Oladele; Jay K Kolls
Journal:  Med Mycol       Date:  2020-11-10       Impact factor: 4.076

5.  Characterization of major surface glycoprotein genes of human Pneumocystis carinii and high-level expression of a conserved region.

Authors:  Q Mei; R E Turner; V Sorial; D Klivington; C W Angus; J A Kovacs
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

6.  Intranasal immunization confers protection against murine Pneumocystis carinii lung infection.

Authors:  J M Pascale; M M Shaw; P J Durant; A A Amador; M S Bartlett; J W Smith; R L Gregory; G L McLaughlin
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

7.  Serum antibody levels to the Pneumocystis jirovecii major surface glycoprotein in the diagnosis of P. jirovecii pneumonia in HIV+ patients.

Authors:  Kpandja Djawe; Laurence Huang; Kieran R Daly; Linda Levin; Judy Koch; Alexandra Schwartzman; Serena Fong; Brenna Roth; Anuradha Subramanian; Katherine Grieco; Leah Jarlsberg; Peter D Walzer
Journal:  PLoS One       Date:  2010-12-09       Impact factor: 3.240

8.  Antibody response to Pneumocystis jirovecii major surface glycoprotein.

Authors:  Kieran R Daly; Laurence Huang; Alison Morris; Judy Koch; Kristina Crothers; Linda Levin; Shary Eiser; Supriya Satwah; Patricia Zucchi; Peter D Walzer
Journal:  Emerg Infect Dis       Date:  2006-08       Impact factor: 6.883

9.  Serologic responses to recombinant Pneumocystis jirovecii major surface glycoprotein among Ugandan patients with respiratory symptoms.

Authors:  Robert J Blount; Leah G Jarlsberg; Kieran R Daly; William Worodria; J Lucian Davis; Adithya Cattamanchi; Kpandja Djawe; Alfred Andama; Judith Koch; Peter D Walzer; Laurence Huang
Journal:  PLoS One       Date:  2012-12-21       Impact factor: 3.240

10.  Enzyme-linked immunosorbent assay and serologic responses to Pneumocystis jiroveci.

Authors:  Kieran R Daly; Judy Koch; Linda Levin; Peter D Walzer
Journal:  Emerg Infect Dis       Date:  2004-05       Impact factor: 6.883

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.